<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340766</url>
  </required_header>
  <id_info>
    <org_study_id>20150290</org_study_id>
    <secondary_id>2016-002191-27</secondary_id>
    <nct_id>NCT03340766</nct_id>
  </id_info>
  <brief_title>Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)</brief_title>
  <official_title>A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b: To determine the maximum tolerated dose (MTD) of blinatumomab in combination with
      pembrolizumab in adult subjects with relapsed or refractory (r/r) DLBCL
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">January 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to study day 63, depending on cohort dosing and schedule</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) will be assessed during each cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Objective response rate (including Complete Response and Partial Response) by Cheson Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Progression Free Survival (PFS) by Cheson Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Subjects followed for survival up to 48 months (24 months after last dose of pembrolizumab)</time_frame>
    <description>Overall Survival (OS) will be determined for 24 months following the last dose of pembrolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Complete Response (CR) rate by Cheson Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>The duration of response (DOR) will be determined using Objective response rate (ORR), Complete response (CR) and Partial Response (PR), and using Cheson Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinatumomab Steady state concentration</measure>
    <time_frame>Up to study day 43, depending on cohort dosing and schedule</time_frame>
    <description>Pharmacokinetic profile of Blinatumomab: Steady state concentration (Css)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinatumomab Clearance rate</measure>
    <time_frame>Up to study day 43, depending on cohort dosing and schedule</time_frame>
    <description>Pharmacokinetic profile of Blinatumomab - Clearance rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembrolizumab Peak Plasma Concentration</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Pembrolizumab Pharmacokinetic parameter: Peak Plasma Concentration (Cmx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembrolizumab Minimum plasma concentration</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Pharmacokinetic profile of Pembrolizumab: Minumum plasma concentration (Cmn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembrolizumab PK Parameter - AUC</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Pharmacokinetic profile of Pembrolizumab: Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Incidence and severity of adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>By Lugano Classification. Exploratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>Up to study week 10</time_frame>
    <description>Programmed death ligand-1 (PD-L1) Exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Lymphocytes (B-cell, T-cell populations, NK cells) and leukocyte</measure>
    <time_frame>Up to study day 64</time_frame>
    <description>Exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral blood cytokine levels</measure>
    <time_frame>Up to study day 22</time_frame>
    <description>Exploratory. Monitor activation of immune effector cells by looking at Th1 and Th2 cytokines and others such as IL-6, IL-10, TNF alpha and INF gamma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Minimal Residual Disease</measure>
    <time_frame>Up to study week 10</time_frame>
    <description>Using Next Generation Sequencing. Exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Patient Reported Outcomes - EQ-5D. Exploratory.</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>EQ-5D. Exploratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Patient Reported Outcomes - FACT-Lymphoma</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>FACT-Lymphoma</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>COHORT Ib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT IIb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT IIIb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT Ia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 15).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT IIa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 19).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT IIIa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 19).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will test the Maximum Tolerated Dose of Blinatumomab in combination with Pembrolizumab identified using cohort design from cohorts Ia/b, IIa/b and IIIa/b tested in Part 1 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Up to 2 cycles of Blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion. The dosing given is dependent on the cohort, and is as follows:
Cohort Ia/b: 9 microgram/day for 7 days followed by 28 microgram/day for the remainder of each cycle.
Cohort IIa/b: 9 microgram/day for 7 days followed by 28 microgram/day for 7 days followed by 112 microgram/day for the remainder of each cycle.
Cohort IIIa/b: 9 microgram/day for 7 days followed by 28 microgram/day for 7 days followed by 56 microgram/day for the remainder of each cycle.
The Maximum Tolerated Dose identified through this cohort design will then be tested in the expansion cohort.</description>
    <arm_group_label>COHORT Ib</arm_group_label>
    <arm_group_label>COHORT IIb</arm_group_label>
    <arm_group_label>COHORT IIIb</arm_group_label>
    <arm_group_label>COHORT Ia</arm_group_label>
    <arm_group_label>COHORT IIa</arm_group_label>
    <arm_group_label>COHORT IIIa</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>BlinCyto</other_name>
    <other_name>AMG 103</other_name>
    <other_name>Formerly known as MT103 or bscCD19xCD3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>One cycle of Pembrolizumab is a 200 milligrams intravenous injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
Treatment start is dependent on the cohort:
Cohort Ia: Study day 15 (where blinatumomab treatment started on study day 1) Cohort IIb, IIb, IIIb: Study day 1 (where blinatumomab treatment also starts on study day 1) Cohort IIa, IIIa: Study day 19 (where blinatumomab treatment stated on study day 1)</description>
    <arm_group_label>COHORT Ib</arm_group_label>
    <arm_group_label>COHORT IIb</arm_group_label>
    <arm_group_label>COHORT IIIb</arm_group_label>
    <arm_group_label>COHORT Ia</arm_group_label>
    <arm_group_label>COHORT IIa</arm_group_label>
    <arm_group_label>COHORT IIIa</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically confirmed Diffuse Large B Cell Lymphoma that is either:

               -  Refractory to first or later treatment, or

               -  First or later relapse AND has received at least 2 prior therapies (one of which
                  can be frontline therapy) or

               -  Relapsed post-autologous HSCT

          -  Have measureable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Life expectancy of ≥ 12 weeks in the opinion of the Investigator

          -  Subject must be able to provide an evaluable core or excisional biopsy prior to the
             start of treatment. Other Inclusion Criteria May Apply

        Exclusion Criteria:

          -  Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic
             leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)

          -  History or presence of clinically relevant Central Nervous System pathology such as
             epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's
             disease, cerebellar disease, organic brain syndrome, or psychosis.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in
             dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of protocol specified
             therapy.

          -  Has undergone prior allogeneic HSCT:

               -  within the last 5 years OR

               -  greater than 5 years ago but has active graft versus host disease (GvHD)
                  requiring systemic treatment.

          -  Has received autologous HSCT within 6 weeks prior to start of treatment. Other
             Exclusion Criteria May Apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL Relapsed post-autologous hematopoietic stem cell transplantation (HSCT)</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Bispecific in combination with PD-1/PD-L1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

